A carregar...
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Many retrospective and prospective studi...
Na minha lista:
| Publicado no: | Korean J Intern Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Korean Association of Internal Medicine
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5432802/ https://ncbi.nlm.nih.gov/pubmed/28352061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2016.190 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|